Member Info for MaryMoo

@TedB and Haydn1 - I agree. I have had my doubts too.

The only reference to Faron/Traumakine I have found here
https://static1.squarespace.com/static/5cde3c7d9a69340001d79ffe/t/5ea3fdaf3459dd34b669d79d/1587805632015/REMAP-CAP+-+COVID-19+Immune+Modulation+Domain-Specific+Appendix+V2.0+-+07+April+2020_WM.pdf

Please see page 43

I'm only thinking that the lack of news could be down to Faron being involved in Phase III trial where the required patient numbers are larger. Therefore, we have to wait for a longer time for results.

When Juho Jalkanen spoke in Faron's R&D day, he referred to an Iranian study with positive interferon beta-1a results. They had used ReciGen. The other drug I've seen in the studies is called Rebif.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275997/

I'm only thinking with my layman hat on that any positive interferon beta-1a studies are good news for Faron/Traumakine. However, if I'm understood correctly, phase III medical trials are double-blind and even medics wouldn't know what drug they're administering. Markku has said himself how it was a shock to receive the previous phase III Traumakine study results as the negative outcome was news to him too.

@TedB The only reference I have found for Remap-Cap & Faron has been in this document. Please search for Faron (page 43). I have posted this before in here but that was many moons ago.

https://static1.squarespace.com/static/5cde3c7d9a69340001d79ffe/t/5ea3fdaf3459dd34b669d79d/1587805632015/REMAP-CAP+-+COVID-19+Immune+Modulation+Domain-Specific+Appendix+V2.0+-+07+April+2020_WM.pdf

I too have had my doubts as Interferon beta-1a studies keep popping up. The other drug names I've seen have been ReciGen and Rebif. However, so far no Traumakine. My only guess is that Traumakine studies possibly include a larger patient sample and results could be coming out later for that reason?

If I've understood it correctly, Phase III trials should be double-blind so even the medics won't know what drug they are administering. Perhaps someone who knows better can clarify this. What I have read from Markku's previous interviews Traumakine's last Phase III trial failure was a surprise for him too. He was fully expecting to have positive results but found out the failure after the results came in. In Faron's R&D day, Juho was referring to some Iranian study with a positive Interferon beta 1a results. One positive Iranian study I managed to find had used ReciGen. Patient sample size was 20.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275997/

My layman thinking says that any positive Interferon beta 1a study is positive news for Traumakine/Faron as well. Faron's moat could possibly be the patented administration method (less interferon needed) and top-quality researchers. Please correct me if I'm totally in the wrong.

Yes. Finland going strong today...
London: 440.20 +25.20 +6.07%
Helsinki: 5.48 +0.81 +17.34%

Thank you for your replies @quesera and @zumzum.

Perhaps someone who has experience on the AIM market and stock markets, in general, is able to say how much CEOs normally talk up their companies? Could they do press interviews in order to raise people's expectations without any substance? Is a pump and dump market manipulation something that CEOs would do? I'd like to think Jalkanen is genuine as he has often expressed how upset he was after the failed trials a couple of years back. Would he be likely to get people's hopes up if he didn't think the results are going to be in Faron's favour?I managed to find one analyst target price for Faron. 5,34 €https://www.marketscreener.com/FARON-PHARMACEUTICALS-OY-24949011/consensus/The analyst is Dr Julie Simmonds. She works for Panmure Gordons that were involved in the latest placing (14 million euros)http://www.panmure.com/people/dr-julie-simmonds/

I'm glad you have FARN on your list. It has had a couple of quiet weeks but it has a tendency to go up in bursts and when it goes up, it goes up fast... It's a dual listing (London & Helsinki). Anxiously waiting for the news from WHO Solidarity Trials to come through. The last two treatment options left in the trial are Remdesivir and Lopinavir/Ritonavir with Interferon beta-1a.

https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments

As soon as I pressed "post message", I thought of Maija. Thanks @cwebb07.

Juho Jalkanen?

If you had a choice I would think anyone would rather be chilling in their log cabin by the lake rather than spend time on planes flying here there and everywhere! Especially in Covid-19 time... So if Mr Jalkanen has put himself on a plane that must have been for a very a good reason.

I first thought this was a recycled article but it could be a positive nudge. Looks like Faron is still as much in the dark what comes to result that the rest of us. Jalkanen seems positive as he now knows that Traumakine studies won't have been contaminated by corticosteroids. He even goes as far as to say that drinks are on him when Faron gets the sales permission for Traumakine. "Tiedän jo, että tulen tarjoamaan samppanjat koko porukalle kun myyntilupa tulee, Jalkanen sanoo."

OilMan, I assure you that is a translation error.

Here's the culprit sentence:
"Tällä hetkellä tiedetään, että enää Traumakinen lääkeaine interferoni-beta ja viruksien jakautumista estävä remdesiviiri ovat mukana tutkimuksessa."

For some reason a word "estävä " causes Google to mistranslate.

What article actually says that only Interferon-Beta and Remdesivir are only candidates left in the study.

I would be very disappointed if that was the case and Faron's IR had not notified investors about it :( Not good.

I've noticed Lago's absence too. I missed my top up window around £3 level and have been waiting for Lago to start selling again. Alas, no luck. I'm a bit too inexperienced trader to understand much about trade volume levels etc. but the activity has been low in the sales front. If I could trust Lago to stay in hiding, I'd happily top-up. However, there has been no announcement that Faron's contract with Lago has come to an end. I've been wondering if the new financial advisors have put a stop for Lago trades until they can assess the situation in full???

I was about to say the same as I spotted "code 1" in London Stock Exchange list. Can't see it yet here on the free version.
https://www.londonstockexchange.com/stock/FARN/faron-pharmaceuticals-oy/trade-recap

I have a soft spot for this company for some reason. I just discovered the videos on its website. So sweet. I think as time goes on Steppe can automate its production line even more and get people to do less backbreaking work. But one has to start somewhere and build it up gradually.
http://www.steppecement.com/cementpacking/

The Line 5 opening ceremony is so sweet. Is the theme tune in the background from Dallas? Love it.
http://www.steppecement.com/line5/jun2014.php

Thank you bigsmoke. It cleared it up for me.
I spent some time reading Steppe's annual report and financials yesterday. I'm a bit sentimental but I really like the company. They seem to be improving the factory every year, aiming to keep the debt level under control and there is always positive indicators of how Steppe is looking after its staff.

I'm fairly new to investing so would appreciate some informative replies. I've understood that if one sells a stock on the ex-div date or after, it is still possible to get the dividends. If so, the selling activity today was due to people selling their shares with a knowledge that they will still receive the dividend payment? What confuses me a bit is the record date? If I sold my shares on ex-div date, I assume I would not be listed in the books on the record date? If I am, why is that? Is there some sort of built -in delay in the system?

Yes Oil, it was discussed some time ago. I just don't know if we ever found out why Faron is listed on four different markets
US OTC - FPHAF
Berlin - 4FR
London - FARN
Helsinki - FARON

We know the reason why London and Helsinki, but why Berlin and US OTC? As far as I've understood, it's not trading in Berlin and the
US yet. Perhaps someone could explain why.

CFO is topping up like the rest of us... Good news! (in my books anyway...) Not sure if it also means that we still have a while to wait for any concrete news...
https://otp.tools.investis.com/clients/uk/faron1/rns/regulatory-story.aspx?cid=2223&newsid=1401324

Apologies if this has been shared already. I recall seeing it before...
https://www.nature.com/articles/s41416-020-0953-0

Conclusions
Clever-1 is a very versatile molecule and its broad impact on dampening antitumour immune responses has only just begun to be recognised. As such, both endothelial and macrophage subsets that express Clever-1 are important mediators of these actions, and their contribution may vary depending on the tumour type (Fig. 4). The dissection of novel mechanisms of cancer immunosuppression and immunotherapy resistance involving the biology of Clever-1-expressing TAMs aims to enable the translation of these research findings from bench to bedside, as is now in progress in the MATINS clinical trial. It is expected to provide solid ground for a new generation of Clever-1 inhibitors that could potentially act as alternative therapies to improve antitumour immune responses, as well as adjuvant strategies to prevent resistance that often occurs during the ICI therapies.

Let's see... based on this interferon on its own will be tested too.

Vergiere said following the development, the DOH will now have “remdesivir plus interferon as the new regimen, vs remdesivir alone (and) vs interferon alone, and standard of care once shipment of interferon arrives.”

https://www.rappler.com/nation/265737-doh-stop-giving-patients-lopinavir-ritonavir-following-experts-advice